DERMABET
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DERMABET (DERMABET).
Betamethasone dipropionate is a corticosteroid that diffuses across cell membranes and binds to glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. It induces phospholipase A2 inhibitory proteins (lipocortins), thereby inhibiting the release of arachidonic acid and decreasing the synthesis of prostaglandins and leukotrienes. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Betamethasone dipropionate is metabolized primarily in the liver via ester hydrolysis to betamethasone, which is further metabolized via CYP3A4-mediated oxidation and glucuronidation. |
| Excretion | Renal (60-70% as unchanged drug and metabolites), biliary/fecal (30-40%) |
| Half-life | Terminal elimination half-life: 3-4 hours; prolonged in hepatic impairment |
| Protein binding | 90-95% bound to albumin |
| Volume of Distribution | 0.5-0.8 L/kg; indicates extensive tissue distribution |
| Bioavailability | Oral: 70-90%; Topical: minimal systemic absorption (approximately 1-2% with intact skin) |
| Onset of Action | Oral: 30-60 minutes; Topical: 2-4 hours for anti-inflammatory effect |
| Duration of Action | Oral: 8-12 hours; Topical: 12-24 hours with occlusive dressing |
| Molecular Weight | 376.43 Da |
Apply a thin layer to affected area once or twice daily. Maximum 50 g per week.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required. |
| Liver impairment | No dose adjustment required. |
| Pediatric use | Apply a thin layer to affected area once daily. Use lowest effective strength for shortest duration. |
| Geriatric use | Use with caution; apply sparingly to small areas for shortest duration due to increased skin atrophy risk. |
| 1st trimester | Topical corticosteroids are generally avoided in the first trimester due to theoretical risk of orofacial clefts, though the risk is low with short-term use of low-potency agents. |
| 2nd trimester | Use with caution; minimal systemic absorption with low to moderate potency topical steroids, but avoid prolonged use on large areas. |
| 3rd trimester | Considered relatively safer than t1, but avoid high potency on large areas due to risk of intrauterine growth restriction and adrenal suppression in fetus. |
Clinical note
Comprehensive clinical and safety monograph for DERMABET (DERMABET).
| Placental transfer | Topical corticosteroids have minimal placental transfer with low potency agents; systemic absorption is negligible with proper use, but high potency or prolonged use may lead to significant transfer. |
| Breastfeeding | Topical corticosteroids are excreted into breast milk in negligible amounts when used sparingly and not on the breast or nipple area. Avoid application to breasts or nipples prior to nursing to prevent infant ingestion. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to betamethasone or any componentUntreated fungal, bacterial, or viral skin infections (e.g., herpes simplex, varicella, tuberculosis)Perioral dermatitisRosacea
| Precautions | Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and unmask latent diabetes. Use on face or intertriginous areas increases risk of adverse effects. Avoid prolonged use or application to large surface areas, especially in children. Do not use with occlusive dressings unless directed. Monitor for local skin atrophy, telangiectasias, and striae. |
| Food/Dietary | No known food interactions. Avoid excessive alcohol consumption as it may exacerbate cutaneous vasodilation or irritation. |
Loading safety data…
| Lactation Rating | L2 (Limited data - probably compatible) |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: Corticosteroids are associated with cleft palate (1-2% increased risk). Second and third trimesters: Increased risk of intrauterine growth restriction, adrenal suppression in the fetus, and preterm delivery with chronic high-dose use. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose (especially in diabetics), signs of infection. Fetal monitoring includes serial ultrasound for growth restriction and adrenal function (e.g., fetal adrenal suppression). Consider monitoring for maternal hypothalamic-pituitary-adrenal axis suppression with prolonged use. |
| Fertility Effects | No established adverse effects on fertility in humans. Corticosteroids may disrupt ovulation at high doses but rarely impact fertility at therapeutic topical doses. |
| Clinical Pearls | DERMABET is a fixed-dose combination of topical betamethasone dipropionate and clotrimazole. Avoid prolonged use on face, groin, or axillae due to risk of skin atrophy. Limit continuous therapy to 2 weeks for intertriginous areas. Do not use with occlusive dressings unless directed. Monitor for signs of secondary infection. In children, use lowest potency and shortest duration due to higher systemic absorption. |
| Patient Advice | Apply a thin layer only to affected skin; avoid contact with eyes, mouth, or open wounds. · Do not use longer than prescribed; overuse may cause skin thinning or systemic side effects. · Do not bandage, cover, or wrap the treated area unless instructed by your doctor. · Wash hands after applying unless treating hands. · Avoid using other topical products on the same area without consulting your doctor. · Inform your doctor if you have diabetes, as topical corticosteroids can affect blood glucose control. · If you are pregnant, planning to become pregnant, or breastfeeding, discuss use with your doctor. |